Intezyne Technologies is a clinical-stage biotechnology company founded in 2004 with headquarters in the United States. The company is dedicated to enhancing the efficacy of cancer treatments by leveraging a range of proprietary assets. Its portfolio is being advanced through various stages of the clinical approval process.
The most recent funding event for Intezyne Technologies was a $10.00M Series A investment, which took place on 06 October 2017. The investment was led by Gaston Capital Partners.
Intezyne Technologies' focused approach to improving cancer treatment effectiveness and its progress in advancing through clinical stages make it an intriguing prospect, showcasing potential for significant impact in the biotechnology and healthcare industries.